SAN FRANCISCO — (NEWSWIRE) Jan 28, 2010 — Biomagnetics Diagnostics Corp. (BMGP.PK), a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, announced today that the Company is initiating several clinical trials in multiple markets, including Kenya and India, and is also in talks with one of the largest hospitals within the social security system of Mexico in order to address the clinical requirements of that market.
Through governmental agencies and blood banks in Kenya and India, Biomagnetics Diagnostics will have access to malaria (as well as other infectious diseases) infected blood that can be used to develop immunoassays and perform clinical trials on the Company’s integrated optical sensor in a cost effective, rapid manner.
At the end of last year, Biomagnetics Diagnostics contacted India’s Health Ministry Blood Bank in New Delhi, which specializes in malaria, with the goal of conducting clinical trials for product commercialization throughout India. In February the Company will meet with the Blood Bank as well as private institutions to initiate the administrative requirements to perform clinical trials. We will also start vetting potential distributors.
The Company is also in talks with Dr. Gustavo Barriga, Chief of the Laboratoria of the Hospital of Infectologia of the Centro Medico Nacional (CMN) La Raza, one of the largest hospitals operated under the social security system of Mexico, to discuss the Integrated Optical Biosensor (IBOS), clinical requirements and commercialization for the Mexican market.
“We are very excited to begin clinical trials of the Company’s IOBS platform,” commented Clayton Hardman, CEO of Biomagnetics Diagnostics. “We believe our integrated optical biosensor platform can significantly change the way point of care (POC) diagnostics are performed. These trials represent an important milestone for the Company and should create strong interest in our system.”
The Biomagnetics Diagnostics IOBS platform, which is made available in part via a technology transfer license from the Los Alamos National Security Laboratory, is a relatively new classification of pathogen detection equipment that uses advanced fiber optic-based technology to detect a wide variety of human and animal pathogens. These devices produced by the Company are specifically designed to be field deployable, ultraportable and very easy to use, allowing for extremely rapid detection of various viral and bacterial pathogens by relatively untrained personnel outside of the laboratory setting.
About Biomagnetics Diagnostics Corp.
Biomagnetics Diagnostics Corporation is an advanced medical device and biotechnology company. The Company’s revolutionary diagnostic systems, which are based on advanced magnetic and optics, test for any viral or bacterial disease using any body fluid. The Company’s technology allows laboratories to perform far more tests in the same amount of time it takes to do a single test via traditional existing methodologies. More information on Biomagnetics Diagnostics Corp. can be seen at www.BiomagneticsBMGP.com.
Contact:
Joe Noel
Biomagnetics Diagnostics Corp.
(925) 922-2560
Source: Biomagnetics Diagnostics Corp.